FDA panel says Cubist anti-infective shows efficacy, safety

March 31 Mon Mar 31, 2014 11:27am EDT

March 31 (Reuters) - Cubist Pharmaceuticals Inc's anti-infective tedizolid for acute bacterial skin infections shows substantial evidence of safety and efficacy, an advisory panel to the U.S. Food and Drug Administration concluded on Monday.

The panel's vote was unanimous. The FDA is not obliged to follow the advice of its expert panels but typically does so. (Reporting by Toni Clarke in Washington; Editing by Bill Trott)